Olivier Lortholary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6379609/publications.pdf

Version: 2024-02-01

14702 53660 20,019 134 45 127 citations h-index g-index papers 136 136 136 16501 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. New England Journal of Medicine, 2002, 347, 408-415.	13.9	3,048
3	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	2.9	2,195
4	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	2.9	1,429
5	Gain-of-function human <i>STAT1</i> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2011, 208, 1635-1648.	4.2	739
6	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	6.3	695
7	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 510-519.	4.6	366
8	Deep Dermatophytosis and Inherited CARD9 Deficiency. New England Journal of Medicine, 2013, 369, 1704-1714.	13.9	362
9	Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study. PLoS Medicine, 2007, 4, e21.	3.9	338
10	Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010. Emerging Infectious Diseases, 2014, 20, 1163-1169.	2.0	322
11	Epidemiology and clinical management of Legionnaires' disease. Lancet Infectious Diseases, The, 2014, 14, 1011-1021.	4.6	314
12	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. New England Journal of Medicine, 2018, 378, 1004-1017.	13.9	296
13	Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. Aids, 2005, 19, 1043-1049.	1.0	289
14	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	3.9	278
15	Autosomal Dominant STAT3 Deficiency and Hyper-IgE Syndrome. Medicine (United States), 2012, 91, e1-e19.	0.4	274
16	An Immune Reconstitution Syndrome-Like Illness Associated withCryptococcus neoformans Infection in Organ Transplant Recipients. Clinical Infectious Diseases, 2005, 40, 1756-1761.	2.9	243
17	Cryptococcus neoformansin Organ Transplant Recipients: Impact of Calcineurinâ€Inhibitor Agents on Mortality. Journal of Infectious Diseases, 2007, 195, 756-764.	1.9	243
18	Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species–induced meningoencephalitis, colitis, or both. Journal of Allergy and Clinical Immunology, 2015, 135, 1558-1568.e2.	1.5	208

#	Article	IF	CITATIONS
19	Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. American Journal of Medicine, 1993, 95, 177-187.	0.6	203
20	Immunocompromised Hosts: Cryptococcosis in Solid Organ Transplant Recipients: Current State of the Science. Clinical Infectious Diseases, 2008, 47, 1321-1327.	2.9	202
21	Primary immunodeficiencies underlying fungal infections. Current Opinion in Pediatrics, 2013, 25, 736-747.	1.0	190
22	International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole. Antimicrobial Agents and Chemotherapy, 2010, 54, 4446-4450.	1.4	158
23	Inherited CARD9 Deficiency in 2 Unrelated Patients With Invasive Exophiala Infection. Journal of Infectious Diseases, 2015, 211, 1241-1250.	1.9	141
24	Adjuvant Corticosteroid Therapy for Chronic Disseminated Candidiasis. Clinical Infectious Diseases, 2008, 46, 696-702.	2.9	140
25	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	13.9	119
26	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. Journal of Autoimmunity, 2017, 80, 10-27.	3.0	114
27	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	3.9	106
28	Allograft Loss in Renal Transplant Recipients with Cryptococcus Neoformans Associated Immune Reconstitution Syndrome. Transplantation, 2005, 80, 1131-1133.	0.5	95
29	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet, The, 2017, 389, 612-620.	6.3	95
30	Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. Aids, 2006, 20, 119-121.	1.0	93
31	Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome. Journal of Infection, 2014, 68, 478-493.	1.7	93
32	The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Medicine, 2017, 43, 652-662.	3.9	92
33	Severe Dermatophytosis and Acquired or Innate Immunodeficiency: A Review. Journal of Fungi (Basel,) Tj ETQq1 1	0,784314 1.5	1 rgBT /Over
34	Arboviruses and pregnancy: maternal, fetal, and neonatal effects. The Lancet Child and Adolescent Health, 2017, 1, 134-146.	2.7	80
35	Fungal endocarditis: current challenges. International Journal of Antimicrobial Agents, 2014, 44, 290-294.	1.1	79
36	Incidence and Risk Factors of Legionella pneumophila Pneumonia During Anti-Tumor Necrosis Factor Therapy. Chest, 2013, 144, 990-998.	0.4	75

#	Article	IF	CITATIONS
37	Chronic pulmonary aspergillosis complicating sarcoidosis. European Respiratory Journal, 2017, 49, 1602396.	3.1	66
38	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	4.6	63
39	Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. Aids, 2012, 26, 2110-2112.	1.0	62
40	Rifabutin: where do we stand in 2016?. Journal of Antimicrobial Chemotherapy, 2016, 71, 1759-1771.	1.3	61
41	Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002–14). Journal of Antimicrobial Chemotherapy, 2017, 72, 1784-1793.	1.3	57
42	Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review Clinical Infectious Diseases, 2018, 66, 1122-1132.	2.9	53
43	Recent advances in the understanding and management of mucormycosis. F1000Research, 2018, 7, 1429.	0.8	53
44	Humans with inherited TÂcell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. Cell, 2021, 184, 3812-3828.e30.	13.5	53
45	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. Clinical Infectious Diseases, 2021, 72, 1268-1278.	2.9	51
46	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	1.3	47
47	Risk of Herpes Zoster in Patients Receiving Anti-TNF-α in the Prospective French RATIO Registry. Journal of Investigative Dermatology, 2012, 132, 726-729.	0.3	46
48	Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. Transplant Infectious Disease, 2018, 20, e12799.	0.7	44
49	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2387-2395.e3.	2.0	42
50	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	2.0	42
51	Imported Acquired Immunodeficiency Syndrome–Related Histoplasmosis in Metropolitan France: A Comparison of Pre–Highly Active Anti-Retroviral Therapy and Highly Active Anti-Retroviral Therapy Eras. American Journal of Tropical Medicine and Hygiene, 2011, 85, 934-941.	0.6	40
52	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 757-763.	1.3	40
53	Fungal Infections in Immunocompromised Travelers. Clinical Infectious Diseases, 2013, 56, 861-869.	2.9	39
54	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus–infected Adults With CD4 Cell Counts <100/Î⅓L: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2019, 68, 688-698.	2.9	38

#	Article	IF	CITATIONS
55	Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections. Journal of Fungi (Basel, Switzerland), 2018, 4, 139.	1.5	34
56	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia, 2020, 34, 1090-1101.	3.3	34
57	Cerebral Phaeohyphomycosis Caused by <i>Rhinocladiella mackenziei</i> in a Woman Native to Afghanistan. Journal of Clinical Microbiology, 2010, 48, 3451-3454.	1.8	33
58	Why are so many cases of invasive aspergillosisÂmissed?. Medical Mycology, 2019, 57, S94-S103.	0.3	33
59	An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1046, 26-33.	1.2	32
60	Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. Aids, 2014, 28, 1593-1602.	1.0	28
61	Legionnaire's Disease in Compromised Hosts. Infectious Disease Clinics of North America, 2017, 31, 123-135.	1.9	28
62	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 775-778.e6.	1.5	28
63	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: AÂretrospective case series. Journal of Allergy and Clinical Immunology, 2013, 132, 997-1000.e4.	1.5	26
64	Evaluation of a New Histoplasma spp. Quantitative RT-PCR Assay. Journal of Molecular Diagnostics, 2021, 23, 698-709.	1.2	25
65	Relevance of EORTC Criteria for the Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival Trends Over a 20-Year Period in France. Clinical Infectious Diseases, 2015, 61, 1273-1280.	2.9	24
66	Isavuconazole Diffusion in Infected Human Brain. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	24
67	Mainly Post-Transplant Factors Are Associated with Invasive Aspergillosis after Allogeneic Stem Cell Transplantation: A Study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Biology of Blood and Marrow Transplantation, 2019, 25, 354-361.	2.0	23
68	Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases, 2020, 79, 1532-1543.	0.5	23
69	Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies. Journal of Clinical Immunology, 2019, 39, 55-64.	2.0	20
70	Mycobacterium genavense as a cause of subacute pneumonia in patients with severe cellular immunodeficiency. BMC Infectious Diseases, 2011, 11, 311.	1.3	19
71	Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	18
72	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. Clinical Infectious Diseases, 2019, 69, 588-595.	2.9	18

#	Article	IF	CITATIONS
73	Azole Susceptibility Profiles of More than 9,000 Clinical Yeast Isolates Belonging to 40 Common and Rare Species. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	17
74	Smoking as a Risk Factor of Invasive Fungal Disease: Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2020, 71, 1106-1119.	2.9	16
75	Fulminant Nocardiosis Due to a Multidrug-Resistant Isolate in a 12-Year-Old Immunocompetent Child. Pediatrics, 2018, 141, .	1.0	15
76	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. Journal of Clinical Immunology, 2021, 41, 185-193.	2.0	15
77	When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy, 2021, 77, 16-23.	1.3	15
78	The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and) Tj ETQq0 0 0 rgBT /Over	rlock 10 Tf	50 ₁ 542 Td (n
79	Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis. American Journal of Transplantation, 2018, 18, 2352-2355.	2.6	14
80	Liquid chromatography–tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 944, 175-181.	1.2	13
81	Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study. Journal of Infection, 2017, 74, 408-417.	1.7	13
82	New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis. Current Neurology and Neuroscience Reports, 2019, 19, 81.	2.0	13
83	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. Clinical Infectious Diseases, 2020, 70, 521-524.	2.9	13
84	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. Clinical Infectious Diseases, 2020, 70, 26-29.	2.9	13
85	Chronic Disseminated Candidiasis During Hematological Malignancies: An Immune Reconstitution Inflammatory Syndrome With Expansion of Pathogen-Specific T Helper Type 1 Cells. Journal of Infectious Diseases, 2020, 221, 1907-1916.	1.9	13
86	Granulocyte Colony Stimulating Factor-induced Exacerbation of Fungus-related Immune Restoration Inflammatory Syndrome: A Case of Chronic Disseminated Candidiasis Exacerbation. Journal of Microbiology, Immunology and Infection, 2010, 43, 339-343.	1.5	12
87	Association of mastocytosis with inflammatory joint diseases: A series of 31 patients. Seminars in Arthritis and Rheumatism, 2014, 44, 362-365.	1.6	12
88	Polyvalent immunoglobulins in neonates after perinatal exposure to measles. Journal of Infection, 2015, 71, 131-134.	1.7	12
89	Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study. Transplantation Direct, 2016, 2, e90.	0.8	12
90	Salvage Strategy for Long-Term Central Venous Catheter-Associated Staphylococcus aureus Infections in Children. Frontiers in Pediatrics, 2018, 6, 427.	0.9	12

#	Article	IF	Citations
91	Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. Blood, 2010, 116, 1982-1982.	0.6	12
92	Nocardiosis Associated with Primary Immunodeficiencies (Nocar-DIP): an International Retrospective Study and Literature Review. Journal of Clinical Immunology, 2020, 40, 1144-1155.	2.0	11
93	Recent advances in managing HIV-associated cryptococcal meningitis. F1000Research, 2019, 8, 743.	0.8	11
94	Voriconazole topical cream formulation: evidence for stability and antifungal activity. International Journal of Antimicrobial Agents, 2020, 56, 106083.	1.1	10
95	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. Journal of Clinical Microbiology, 2020, 59, .	1.8	10
96	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. Aids, 2020, 34, 1425-1428.	1.0	9
97	Risk of Lung Allograft Dysfunction Associated With Aspergillus Infection. Transplantation Direct, 2021, 7, e675.	0.8	9
98	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy–NaĀ⁻ve and –Experienced Patients in Sub-Saharan Africa. Open Forum Infectious Diseases, 2021, 8, ofab397.	0.4	9
99	Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	8
100	Successful Treatment of $\langle i \rangle$ Saksenaea $\langle i \rangle$ sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	8
101	Zygomycosis After Allogeneic Hematopoietic Stem Cell Transplantation: A French Multicenter Cohort Study (2003-2008). Blood, 2010, 116, 1263-1263.	0.6	8
102	Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Research, 2018, 7, 661.	0.8	7
103	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: AAstudy of a national retrospective cohort of 1375 patients over 10 years. Journal of Allergy and Clinical Immunology, 2022, 149, 2116-2125.	1.5	7
104	Acute reversible pancreatitis induced by posaconazole. Journal of Antimicrobial Chemotherapy, 2017, 72, 628-630.	1.3	6
105	AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. BMJ Open, 2019, 9, e026288.	0.8	6
106	Failure of multiplex meningitis/encephalitis (ME) NAT during cryptococcal meningitis in solid organ recipients. Transplant Infectious Disease, 2020, 22, e13263.	0.7	6
107	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2021, 8, ofab066.	0.4	6
108	Current Spectrum of Infections in Patients with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2021, 41, 1266-1271.	2.0	6

#	Article	IF	Citations
109	Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations. Antimicrobial Agents and Chemotherapy, 2022, 66, e0172521.	1.4	6
110	A neuropathological study of cerebrovascular abnormalities in a signal transducer and activator of transcription 3–deficient patient. Journal of Allergy and Clinical Immunology, 2015, 136, 1418-1421.e5.	1.5	5
111	Cerebral histoplasmosis caused by <i>Histoplasma capsulatum</i> var. <i>duboisii</i> in a patient with no known immunodeficiency. Journal of Travel Medicine, 2021, 28, .	1.4	5
112	Stewardship program on carbapenem prescriptions in a tertiary hospital for adults and children in France: a cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1039-1048.	1.3	5
113	Morocco as a possible source for acquisition of Rhinocladiella mackenziei. PLoS Neglected Tropical Diseases, 2021, 15, e0009563.	1.3	5
114	Emergence of azole resistant-Aspergillus fumigatus infections during STAT3-deficiency. Journal of Medical Microbiology, 2020, 69, 844-849.	0.7	5
115	Thalidomide for steroidâ€dependent chronic disseminated candidiasis after stem cell transplantation: A case report. Transplant Infectious Disease, 2017, 19, e12637.	0.7	4
116	Defining standards of CARE for invasive fungal diseases in solid organ transplant patients. Journal of Antimicrobial Chemotherapy, 2019, 74, ii16-ii20.	1.3	4
117	Cryptococcus gattii in Patients with Lymphoid Neoplasms: An Illustration of Evolutive Host–Fungus Interactions. Journal of Fungi (Basel, Switzerland), 2021, 7, 212.	1.5	4
118	A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. Journal of Clinical Immunology, 2019, 39, 702-712.	2.0	3
119	Non-Aspergillus Fungal Infections in Chronic Granulomatous Disease. Current Fungal Infection Reports, 2019, 13, 59-66.	0.9	3
120	Fulminant arterial vasculitis as an unusual complication of disseminated staphylococcal disease due to the emerging CC1 methicillin-susceptible Staphylococcus aureus clone: a case report. BMC Infectious Diseases, 2019, 19, 302.	1.3	3
121	Devastating Gynecological Infections in Women with STAT3 Deficiency. Clinical Infectious Diseases, 2020, 71, e186-e190.	2.9	3
122	Thalidomide in Advanced Mastocytosis. Results from an Open-Label, Multicentric, Phase II Study. Blood, 2011, 118, 1754-1754.	0.6	3
123	Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis. Blood. 2012. 120. 4913-4913.	0.6	3
124	Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 783-793.	1.3	2
125	"Chronic Disseminated Aspergillosis,―a Novel Fungal Immune Reconstitution Inflammatory Syndrome. Open Forum Infectious Diseases, 2020, 7, ofaa175.	0.4	2
126	Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1356-1364.e2.	2.0	2

#	Article	IF	CITATIONS
127	Teaching Neurolmages: Aspergillosis-induced vasculitis presenting as ischemic stroke in an immunocompetent patient. Neurology, 2019, 92, e2618-e2619.	1.5	1
128	Case Report: Invasive Cryptococcosis in French Guiana: Immune and Genetic Investigation in Six Non-HIV Patients. Frontiers in Immunology, 2022, 13, 881352.	2.2	1
129	Identification of <i>Streptomyces</i> spp. in a Clinical Sample: Always Contamination? Results of a French Retrospective Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	1
130	Procalcitonin use for the screening of bacterial infections in pregnant women in the emergency ward: A prospective study. Journal of Infection, 2021, 83, e4-e5.	1.7	0
131	French-Brazilian Survey On Pregnancy in Sickle Cell Disease A Study of the International Sickle Cell Disease Observatory. Blood, 2012, 120, 3215-3215.	0.6	O
132	Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study. Blood, 2014, 124, 3254-3254.	0.6	0
133	Prognostic Factors of Infections and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA): A Prospective Study. Blood, 2014, 124, 1917-1917.	0.6	0
134	Omalizumab: Efficacy and Safety in Mast Cell Disorders. Blood, 2018, 132, 4280-4280.	0.6	0